期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

艾滋病疫苗与免疫

AIDS Vaccines and Immunity
下载PDF
导出
摘要 艾滋病(获得性免疫缺陷综合征)是由感染性艾滋病病毒所引起严重危害人类健康的疾病,它是一种病死率高、传播途径广的传染性疾病。艾滋病病毒通过攻击CD4+T细胞来破坏机体的免疫系统,研制出艾滋病疫苗是控制此病的最有效手段,而目前的研究成果并不理想,仍需要进一步探究免疫系统与艾滋病的发生发展间的相互作用。 Acquired immune deficiency syndrome （AIDS） is caused by human immunodeficiency vi rus （HIV）, and harms human health seriously. It is an infectious disease with high mortality and wide spread pathway. HIV disrupts human immune system through attacking CD4＋T cells. The development of an AIDS vaccine is the most effective method to control the disease, but the results of the current study is not ideal, it is still needed to further investigate the interaction of immune system and AIDS development.
作者 张秋瑾 袁桂峰
机构地区 桂林医学院免疫学教研室
出处 《华夏医学》 CAS 2014年第2期159-161,共3页 Acta Medicinae Sinica
关键词 艾滋病 疫苗 细胞毒T淋巴细胞 中和抗体 acquired immune deficiency syndrome vaccine cytotoxic T lymphocyte neutralizing antibodies
分类号 R512.91 [医药卫生—内科学]
  • 相关文献

参考文献15

  • 1AJ M,BF H. Lessons learned from HIV-1 vaccine trials: new priorities and directions[J]. Nat Immunol, 2012, 13 (5) :423-427.
  • 2Cohen J. AIDS vaccine research. HIV natural resistance field finally overcomes resistance[J]. Science, 2009,326 (5959) : 1476-1477.
  • 3Ahn S, Sung Y. AIDS vaccine development:the past, the pres- ent, and the future[J]. Immune Netw, 2009,9 (1) : 1-3.
  • 4朱雁飞,李怀慧,李玉婷,孙明.艾滋病疫苗研究现状[J].医学综述,2010,16(16):2457-2459. 被引量：6
  • 5张健慧,邵一鸣.STEP试验对艾滋病疫苗研究领域的挑战[J].中国艾滋病性病,2009,15(1):82-84. 被引量：2
  • 6Hammer S M, Sobieszczyk M E, Janes H, et al. Efficacy trial of a DNA//rAd5 HIV-1 preventive vaccine[J]. N En- gl J Med,2013,369(22) :2083-2092.
  • 7傅颖嫒,冷静.医学免疫学[M].西安:世界图书出版公司,2011:86-88.
  • 8Buckheit R W, Silieiano R F,Blankson J N. Primary CD8+ T cells from elite suppressors effectively eliminate non- productively HIV-1 infected resting and activated CD4+ T eells[J]. Retrovirology, 2013,10 : 68.
  • 9AB M, RA K. CD8+ T cells in preventing HIV infection and disease[J]. AIDS,2012,26(10) : 1281-1292.
  • 10王芳宇,罗进贤,张添元.HIV疫苗研究进展[J].中国病毒学,2004,19(1):87-91. 被引量：3

二级参考文献109

  • 1Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection[J].Proc Natl Acad Sci USA,2003,100(7) :4144 - 4149.
  • 2Hirbod T, Kaul R, Reichard C, et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers [ J ] . AIDS, 2008, 22 (6) :727-735.
  • 3Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human nantralizing antibodies[J]. Nat Med, 2005,11 (6) :615-622.
  • 4Ruppach H, Nara P, Raudonat I, et al. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes[J] .J Virol,2000,74(12) :5403-5411.
  • 5Zwick MB, Wang M, Poignard P, et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies [ J ] . J Virol, 2001,75 (24) : 12198-12208.
  • 6Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques [J] .AIDS, 2003,17(3) :301 - 309.
  • 7Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of logn-term survivors of human immunodeficieney virus type 1 infection[J]. N Engl J Med, 1995,332(4) : 201 - 208.
  • 8Humbert M,Antoni S, Brill B, et al, Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma[J] .Eur J Immunol,2007,37(2) :501 - 515.
  • 9Khurana S, Kennedy M, King LR, et al. Identification of a linear peptide recognized by monoclonal antibody 2137 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity[ J ]. J Virol, 2005,79 ( 11 ) :6791 - 6800.
  • 10Beirnaert E, Nyambi P, Willems B, et al. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M(env clade A-H)and group O Primary HIV-1 isolates[ J ]. J Med Virol, 2000,62 ( 1 ) : 14 - 24.

共引文献11

华夏医学
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部